In the News

  • Twin Cities Doctors Experiment with a Single Price, Single Bill for Surgery

    The Star Tribune, 23 April 2013

    Rajeev Kapoor, A.T. Kearney partner, discusses the Affordable Care Act and its efforts to make health care more patient-friendly and cost-effective.

    More

  • Outcomes-Driven Models Will Change Retail Rx

    Chain Drug Review, 22 April 2013

    Express Scripts Inc. and Wal­green Co. highlight the zero-sum nature of the traditional relationship between retailers and payers; the new approach will trigger massive upstream changes in health care that will alter the very role of pharmacies.
    ©2013 Chain Drug Review, Racher Press

    PDF

  • A Better Way to Engage with Suppliers

    Supply Chain Quarterly, Q4 2012

    This article discusses the three step process for supplier segmentation, supplier-specific action plans, and the rules of engagement in order to better develop and maintain collaborative relations with far-flung suppliers.

    PDF

  • The Shift Towards Wellness—An Exclusive Interview With Rajeev Kapoor

    Engage Healthcare Today, 21 February 2013

    Rajeev Kapoor shares his insights on the changes currently occurring within the American healthcare system, what's causing them, and the technologies that are helping to drive them.

    More

  • Older Consumers Need Friendlier Packaging

    Chain Drug Review, July 15 2012

    Today, packaging for retail is more than choosing paper, shrink wrap, color, and fonts. It also requires thinking about aging consumers and then rethinking everything you know about product presentation.

    PDF

  • Retail Art, Science Needed to Reach Mature Consumers

    Chain Drug Review, 25 June 2012

    Selling to mature consumers requires a new taxonomy—one that uses smaller and smaller sub-segments to gain a better understanding of their needs.

    PDF

  • A.T. Kearney Releases Report Designed to Help Achieve Stakeholder Confidence in Mobile Health

    13 November 2012

    Healthcare will always be a challenge as a result of rising costs, access, barriers to reform, and power struggles. Mobile health aims to lower cost interactions, provide increased access, and add value through up-to-date diagnosis and prevention.

    More

  • Mobile Health—How to Make It Pay

    November 2011

    Mobile health (mHealth) offerings promise to improve healthcare delivery and provide revenue for service providers—but adoption and monetizing the opportunity will require changes to the way the industry does business.

    More

  • A Collaborative Strategy Aims to Enhance Care for Seniors

    Chain Drug Review, 27 August 2012

    Retail pharmacy and other health care professionals are rapidly adopting virtual integration to manage chronic diseases and improve standards

    PDF

  • Mature Consumers to Shape the Future of Retail Pharmacy

    Chain Drug Review, 23 April 2012

    What are the most important opportunities and challenges that the mature consumer presents to retail pharmacy operators?

    PDF

  • Mature Consumers Empowered by Technology

    Chain Drug Review, 21 May 2012

    Expert data analysis and technology-enabled personalized services will help drug stores give mature shoppers the personal touch they expect.

    PDF

  • Mature Consumers: What Drug Chains Need to Know

    Chain Drug Review, 21 November 2011

    As this customer group grows and gains purchasing power, smart companies will adjust their strategies accordingly.

    PDF

  • Pharmaceuticals out of Balance: Reaching the Tipping Point

    21 September 2009

    A.T. Kearney presents evidence that the current pharmaceutical model may become irrelevant in the context of 21st century's global healthcare needs. With the current dialogue on healthcare reform and the healthcare system in urgent need of restructuring, there is a commensurate impact on the pharmaceutical industry.

    More

  • Farming Out Pharma

    Chaina, November/December 2010

    China's pharma cost advantage will erode as inflation rises, currency appreciates, and tax rebate structures evolve.

    More

  • How to Unlock $43 Billion by Improving Working Capital Management

    PharmaPro, April 2010

    Pharmaceuticals can save billions to invest in value-generating initiatives.

    More

  • Will China Lose Its Cost-Competitiveness in Pharma Manufacturing?

    Life Science Leader, September 2010

    As China's pharmaceutical manufacturing market evolves, Western companies must choose among solutions with varying degrees of complexity and reward. 

    More

  • In the Eye of the Beholder: of Values & Value - 2

    eyeforpharma.com, 5 November 2009

    Pharma Expert Contributor, Fatima Moncrieffe, explores the concept of value in the pharmaceutical industry, referring to A.T. Kearney's research and experts, who explain that the current U.S. debate is a critical issue for the entire world.

    More

  • Pharma at the Tipping Point III: From R&D to Markets

    eyeforpharma.com, 21 October 2009

    Healthcare demand is shifting rapidly toward the developing world, where 96% of global population growth is expected over the next 50 years. For pharmas faced with pricing pressures in developed markets, emerging markets will become too attractive to continue to ignore, and pharmas, A.T. Kearney says, will need to establish prices in a way that maximizes revenue over a drug's entire lifecycle and across global markets.

    More

  • Pharma at the Tipping Point II: Emerging Markets

    eyeforpharma.com, 21 October 2009

    Healthcare demand is shifting rapidly toward the developing world, where 96% of global population growth is expected over the next 50 years. For pharmas faced with pricing pressures in developed markets, emerging markets will become too attractive to continue to ignore, and pharmas, A.T. Kearney says, will need to establish prices in a way that maximizes revenue over a drug's entire lifecycle and across global markets.

    More

  • Pharma at the Tipping Point I: Price Versus Value

    eyeforpharma.com, 21 October 2009

    Why is the industry operating on the precipice? A.T. Kearney observes that even as healthcare budgets are rising, drug sales in most developed countries are forecast to be flat. Pricing pressures are increasing globally, and even the normally safe haven of the U.S. has become a challenging market. The problems, A.T. Kearney says, are symptoms of a shift in the nature of healthcare systems.

    More

In the News

Read insights from A.T. Kearney consultants quoted in the media.

Global Leaders

Jonathan Anscombe
Jonathan Anscombe
Europe, Middle East, and Africa
Vikram Chakravarty
Vikram Chakravarty
Asia Pacific
David Hanfland
David Hanfland
Global
Americas